DGAP-News: Adrenomed AG / Key word(s): Study
07.02.2019 / 11:00
The issuer is solely responsible for the content of this announcement.
Adrenomed AG announces publication of Phase II trial design of Adrecizumab to treat septic shock
– Ongoing proof-of-concept trial AdrenOSS-II testing Adrecizumab in early septic shock
– Adrecizumab is a first-in-class antibody targeting Adrenomedullin, to rescue vascular function
– Vascular integrity, regulated by Adrenomedullin, is key to preventing vascular leakage and septic shock
Hennigsdorf (Germany) February, 7, 2019 – Adrenomed AG, the vascular integrity company, today announced that the Phase II clinical trial design of AdrenOSS-II was published by the peer-reviewed open access journal BMJ Open. The currently ongoing Phase II trial is conducted to assess the safety and efficacy of the monoclonal antibody Adrecizumab in patients with early septic shock, a life-threatening condition with very high unmet medical need.
The biomarker-guided, randomized, double-blind, placebo-controlled, multicenter proof-of-concept AdrenOSS-II trial is evaluating the safety, tolerability and efficacy of Adrecizumab in 300 patients with early septic shock and elevated blood levels of the vasoprotective peptide Adrenomedullin (bio-ADM(R)). The primary endpoints are safety and tolerability of Adrecizumab over a 90-day period. A key secondary endpoint is the Sepsis Support Index (SSI) defined as days with organ support or death within 14 days. The AdrenOSS-II trial started in December 2017 and is currently running in about 30 centers throughout Germany, Belgium, France and the Netherlands (NCT03085758). To date, 150 patients have been enrolled. Full details of the Phase II trial design have now been published on BMJ Open.
Adrenomed’s first-in-class antibody Adrecizumab specifically targets Adrenomedullin, an essential regulator of vascular integrity to treat life-threatening conditions associated with increased vascular leakage, congestion and shock. Adrenomedullin (bio-ADM(R)) was validated as critical biomarker and target in the AdrenOSS-I study, which demonstrated a correlation between high plasma levels of bio-ADM(R) and organ dysfunction as well as higher mortality rates in patients with sepsis and septic shock (NCT02393781). The full article was recently published in Critical Care. Adrecizumab demonstrated an excellent safety profile in two Phase I trials (NCT02991508, NCT03083171, British Journal of Clinical Pharmacology)., , 
About Adrenomedullin (bio-ADM(R))
About Adrecizumab’s mode of action
bio-ADM(R) is a registered trademark of sphingotec GmbH.
07.02.2019 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG.
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.